Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on October 30th, 2015% (Public Domain Pictures, Pixabay)
30 October 2015. A new eye-drop treatment for the underlying causes of glaucoma is being developed in a collaboration between a biotechnology enterprise spun-off from Northwestern University and a company that acquires biomedical research assets. Financial aspects of the deal between Mannin Research Inc. in Toronto, Ontario, Canada and . . . → Read More: Biotech, Accelerator to Partner on Glaucoma Treatment
By Alan, on October 30th, 2015% Electric vehicle charging station (Steve Jurvetson, Flickr)
30 October 2015. A research group at University of Cambridge in the U.K. unveiled a new design that meets some of the obstacles plaguing lithium-air batteries, considered a major improvement over lithium-ion batteries now used to power mobile devices, computers, and electric cars. The team from . . . → Read More: New Design Advances Lithium-Air Battery
By Alan, on October 29th, 2015% (National Cancer Institute)
29 October 2015. An early-stage clinical trial is recruiting participants to test a peptide that illuminates tumor cells to be removed in breast cancer surgery. The study is testing the experimental product made by Avelas Biosciences Inc., a biotechnology company in La Jolla, California.
The clinical trial is enrolling individuals . . . → Read More: Trial Underway Testing Breast Cancer Surgical Aid
By Alan, on October 29th, 2015% Flexible sensors fabricated on silicone wafer (Univ. of California, San Diego)
29 October 2015. Engineers at University of California in San Diego developed a process that simplifies production of flexible electronic sensors worn on the skin for medical diagnostics. The team from the lab of bioengineering professor Todd Coleman published its findings in . . . → Read More: Faster Process Devised for Skin-Patch Sensors
By Alan, on October 28th, 2015% Amin Karami (University at Buffalo)
28 October 2015. A heart pacemaker — the device regulating heartbeats of people with slow or irregular heart rhythms — is being designed to draw power from the beating heart itself and work with next-generation devices that operate inside the heart without wires or leads. Engineers from University . . . → Read More: Heart-Powered Leadless Pacemaker in Development
By Alan, on October 28th, 2015% Sliced turmeric roots (Bames24, Wikimedia Commons)
28 October 2015. A university biochemistry lab and spin-off enterprise developing drugs from plants are collaborating on a process for extracting a key ingredient for an anti-inflammatory compound from the common spice turmeric. The project, bringing together the lab of biochemistry professor David Gang at Washington State . . . → Read More: Univ Lab, Spin-Off Developing Drug from Turmeric
By Alan, on October 27th, 2015% Screen shots from EPV app (itunes.apple.com)
27 October 2015. A new iPhone app allows women to report on the health of their placentas as their pregnancies develop, in a research study of placenta health to help reduce fetal death. The app is designed by researcher Harvey Kliman at Yale University medical school, director . . . → Read More: Mobile App Collecting Placenta Health Data
By Alan, on October 26th, 2015% Updated 21 November 2015. The survey is now closed. Thank you for taking part.
26 October 2015. Our survey conducted with with researcher Paige Brown Jarreau ends this Friday, 20 November 2015. If you planned on taking part in the survey, please do so today. By participating, you’ll be helping me improve Science and Enterprise . . . → Read More: Survey ends 20 November 2015
By Alan, on October 26th, 2015% (NIH.gov)
26 October 2015. A Boston biotechnology company is licensing gene-editing technologies from a nearby start-up to design treatments for cystic fibrosis and inherited blood disorders, including sickle cell disease. Vertex Pharmaceuticals, in Boston, received rights to techniques known as CRISPR-Cas9 in a deal that could bring CRISPR Therapeutics, founded in April 2014, . . . → Read More: Gene Editing Licensed for Inherited Disease Treatments
By Alan, on October 23rd, 2015% Mice receiving FDA-approved tofacitinib or ruxolitinib regrew nearly all their hair, center and right; drug was applied only to the right side of each mouse. Little to no hair growth occurred in control mice during the same time frame, left. (Columbia University Medical Center)
23 October 2015. Research originally designed to study hair . . . → Read More: Two Current Drugs Shown Also to Promote Hair Growth
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
You must be logged in to post a comment.